Quantcast

Latest End point of clinical trials Stories

2015-05-01 08:28:40

SUNNYVALE, Calif., May 1, 2015 /PRNewswire/ -- Pharmacyclics, Inc.

2015-03-27 08:27:02

Patients Too Sick for Enrollment in Phase III Trial for Newly Diagnosed GBM BETHESDA, Md., March 27, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc.

2015-02-23 08:28:53

Analysis of 285 Patient Subgroup Shows an Impressive Statistically Significant 59% Improvement in Overall Survival LAWRENCEVILLE, N.J., Feb.

2015-01-22 08:29:53

Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.

2014-11-14 08:27:59

Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.

2014-10-17 08:25:55

SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-08-29 23:07:08

New research suggests that how quickly mesothelioma progresses after treatment may predict the likelihood of survival better than treatment response. Raleigh,

2014-08-11 08:29:14

Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug.

2014-07-28 08:29:13

Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: